TuHURA Biosciences, Inc. (HURA) – What Are Investment Firms Thinking About This Stock?

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $9.00.

A number of research firms have issued reports on HURA. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, August 18th.

Get TuHURA Biosciences alerts:

Check Out Our Latest Stock Report on HURA

Institutional Trading of TuHURA Biosciences

Several hedge funds have recently added to or reduced their stakes in HURA. BlackRock Inc. acquired a new position in shares of TuHURA Biosciences during the second quarter worth approximately $1,615,000. Apollon Wealth Management LLC grew its stake in shares of TuHURA Biosciences by 17.7% in the first quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock worth $283,000 after acquiring an additional 23,717 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of TuHURA Biosciences in the first quarter worth $251,000. Bank of New York Mellon Corp acquired a new stake in shares of TuHURA Biosciences in the second quarter worth $285,000. Finally, WealthShield Partners LLC acquired a new stake in shares of TuHURA Biosciences in the first quarter worth $164,000. Institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Trading Down 4.7%

NASDAQ:HURA opened at $1.81 on Wednesday. The company’s 50 day moving average is $2.09 and its 200-day moving average is $2.22. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $3.43. The firm has a market cap of $115.35 million, a price-to-earnings ratio of -3.35 and a beta of -0.21.

TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. Equities analysts anticipate that TuHURA Biosciences will post -0.55 EPS for the current year.

About TuHURA Biosciences

(Get Free Report)

TuHURA Biosciences, Inc (NASDAQ:HURA) is a clinical-stage biotechnology company focused on developing therapies designed to overcome immune suppression in the tumor microenvironment and improve responses to cancer treatment. The company’s research is centered on immuno-oncology approaches intended to stimulate both innate and adaptive immune responses against tumors.

TuHURA’s lead program, IFx-2, is an investigational intratumoral immunotherapy and cancer vaccine candidate designed to reprogram the tumor environment and promote an immune response.

Featured Stories

• Five stocks we like better than TuHURA Biosciences
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs

Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.